.svg)
%20(squoosh).jpg)
Can biotech stocks beat the S&P 500?
We don't tell you every stock is a buy. But our research occasionally uncovers hidden gems. From our inception in May 2022 through April 2, 2024, stocks that earned our coveted Asymmetric Opportunity label delivered an average return of 26.2% and outperformed the S&P 500 by 6.7%.
-cropped.svg)
.svg){kind=small}
.svg){kind=small}